Current research on the nuclear matrix protein NMP22 in the diagnosis of bladder cancer caused the NMP22 BladderChek test to obtain the FDA recommendation as a bedside “point-of-care” test for the rapid detection of cancer in risk groups in combination with cystoscopy. This evidence concerns the gene NUMA1 and urinary bladder cancer.